Xencor

Xencor, Inc. is biopharmaceutical company, which engages in the development of engineered monoclonal antibody therapeutics to treat severe and life-threatening diseases. Its proprietary technology platform, XmAb, is used to create next-generation antibody product candidates designed to treat autoimmune and allergic diseases, cancer, and other conditions. The company was founded by Bassil I. Dahiyat and Stephen L. Mayo in August 1997 and is headquartered in Monrovia, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Xencor reports strong earnings, focuses on innovative pipeline strategies

Xencor's strong financial performance and promising pipeline programs position it well for growth
Unique mechanisms and designs offer competitive advantages in oncology and autoimmune disease treatments
Challenges like revenue expectations and validation requirements are being addressed strategically
Opportunities for collaborations and program optimizations pave the way for future success

Xencor advances internal portfolio with strategic focus on impactful targets

Xencor's Q1 2023 Earnings Call highlighted progress in their internal development portfolio, welcoming a new Chief Development Officer and emphasizing innovative therapeutic formats.
While facing challenges in data updates and program differentiation, the company's strategic focus on impactful targets and early clinical development positions them for future success.
Opportunities lie in expanding therapeutic programs, leveraging royalties, and exploring new avenues for growth, signaling a promising trajectory for Xencor in the biopharmaceutical landscape.

Xencor reports robust Q2 earnings and pipeline advancements

Xencor's Q2 2023 earnings call showcased strong performance in royalties and collaborations
The company's diverse pipeline and focus on safety and selectivity present opportunities
Challenges include addressing safety concerns and finalizing regimen for advancement
Overall, Xencor remains optimistic about future updates and pipeline progress

Xencor reports robust Q3 earnings, advances novel oncology therapeutics

Xencor's Q3 earnings call highlighted a strong financial performance, strategic pipeline adjustments, and progress in developing novel antibody-based therapeutics for oncology. The company is focused on maintaining asset potential through royalty deals and advancing internal pipeline candidates targeting solid tumors.

Xencor reports robust clinical data for vudalimab in prostate cancer

Xencor's Q4 earnings call showcased strong clinical data for vudalimab in prostate cancer, highlighting its efficacy and safety profile. The company's strategic focus on T-cell engagers and XmAb bispecific technology positions it well for future growth and innovation in solid tumor targeting.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Xencor, Inc. is a biopharmaceutical company, which engages in the development of engineered monoclonal antibody therapeutics to treat severe and life-threatening diseases. Its proprietary technology platform, XmAb, is used to create next-generation antibody product candidates designed to treat autoimmune and allergic diseases, cancer, and other conditions. The company was founded by Bassil I. Dahiyat and Stephen L. Mayo in August 1997 and is headquartered in Monrovia, CA.

Xencor (XNCR) came out with a quarterly loss of $0.71 per share versus the Zacks Consensus Estimate of a loss of $0.98. This compares to loss of $0.40 per share a year ago.

Xencor (XNCR) Reports Q3 Loss, Tops Revenue Estimates

PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today reported financial results for the third quarter ended September 30, 2024 and provided a review of recent business and clinical-stage program updates. “In September, we provided updates across our clinical pipeline of XmAb® bispecific T-cell engagers in oncology and introduced our new autoimmune p.

Xencor Reports Third Quarter 2024 Financial Results

PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today announced that it has initiated dosing of healthy volunteers in the first-in-human study of XmAb®942, an investigational high-potency extended half-life anti-TL1A antibody. Xencor continues to expect initial data from the ongoing study during the first half of 2025. “An anti-TL1A antibody enginee.

Xencor Doses First Subject in Phase 1/2 Study of XmAb®942 in Development for Patients with Inflammatory Bowel Disease

The average of price targets set by Wall Street analysts indicates a potential upside of 68.2% in Xencor (XNCR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Does Xencor (XNCR) Have the Potential to Rally 68.16% as Wall Street Analysts Expect?

Xencor (XNCR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Xencor (XNCR) Expected to Beat Earnings Estimates: Should You Buy?

The average of price targets set by Wall Street analysts indicates a potential upside of 67.2% in Xencor (XNCR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wall Street Analysts Predict a 67.2% Upside in Xencor (XNCR): Here's What You Should Know

PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today announced that preclinical data on XmAb942 were published in a poster to be presented during United European Gastroenterology (UEG) Week on Tuesday, October 15 in Vienna, Austria. XmAb942 is a high-potency, extended half-life, investigational anti-TL1A antibody to be developed for patients with i.

Xencor Presents Preclinical Data on XmAb942, a High-Potency Extended Half-Life Anti-TL1A Antibody, to be Developed for Patients with Inflammatory Bowel Diseases

PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today announced that Dagmar Rosa-Bjorkeson has informed the Company that she will not stand for reelection to the Company's Board of Directors at the 2025 Annual Meeting of Stockholders. Ms. Rosa-Bjorkeson has served as a director since 2019 and plans to pursue another business opportunity. Xencor will.

Xencor Announces Upcoming Change to Board of Directors

PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (“Xencor”) (Nasdaq: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today announced the closing of its previously announced underwritten public offering of 8,093,712 shares of its common stock at a price to the public of $18.00 per share, which includes the exercise in full by the underwriters of their option to purchase up to 1,458,600 additional shares of.

Xencor Announces Closing of Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Monotherapy and combination dose cohort data from the phase 2 study, using vudalimab for the treatment of patients with mCRPC, expected 1st half of 2025. The global metastatic castrate-resistant prostate cancer treatment market size is projected to reach $20.70 billion by 2031. XmAb942 is a candidate in the company's pipeline which has the potential to become the best in class anti-TL1A inhibitor for the treatment of autoimmune disorders like UC and CD.

Xencor: Vudalimab Development Along With Hidden Gem Candidate

Xencor (XNCR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Xencor (XNCR) Surges 10.5%: Is This an Indication of Further Gains?

PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (“Xencor”) (Nasdaq: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today announced the pricing of its underwritten public offering of (i) 6,635,112 shares of its common stock at a price to the public of $18.00 per share and (ii) pre-funded warrants to purchase up to an aggregate of 3,088,888 shares of common stock at a price to the public of $17.99 per pre-.

Xencor Announces Pricing of $175 Million Public Offering of Common Stock

PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (“Xencor”) (Nasdaq: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today announced that it has commenced an underwritten public offering of shares of its common stock, or, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase shares of common stock. Xencor also intends to grant the underwriters a 30-day option to purch.

Xencor Announces Proposed Public Offering of Common Stock

XNCR moves four new XmAb drug development programs for autoimmune diseases. It also provided favorable updates for two of its oncology drug candidates.

Xencor Stock Gains 23% on Encouraging Pipeline Advancements

PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today announced four new XmAb® programs in development for the treatment of patients with autoimmune diseases and provided updates from dose-escalation studies evaluating its first-in-class oncology programs, including XmAb819 (ENPP3 x CD3) in patients with advanced clear cell renal cell carcinoma and.

Xencor Announces XmAb Drug Candidates in Autoimmune Disease with Near-Term Clinical Plans and Shares Clinical Progress in Early-Stage Oncology Programs

PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today announced that management will host a webcast and conference call at 8:00 a.m. ET (5:00 a.m. PT) on Monday, September 9, 2024 to introduce new XmAb® programs in development for the treatment of patients with autoimmune diseases and to provide updates on continued progress in dose escalation with.

Xencor to Host Research & Development Webcast and Conference Call on Monday, September 9, 2024

Xencor (XNCR) came out with a quarterly loss of $1.07 per share versus the Zacks Consensus Estimate of a loss of $0.85. This compares to loss of $0.37 per share a year ago.

Xencor (XNCR) Reports Q2 Loss, Misses Revenue Estimates

PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today reported financial results for the second quarter ended June 30, 2024 and provided a review of recent business updates and internal clinical-stage programs. “Xencor's clinical focus is developing high-potential, first-in-class bispecific T-cell engagers and additional XmAb® candidates that leverag.

Xencor Reports Second Quarter 2024 Financial Results

PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, announced it will regain exclusive worldwide rights to plamotamab, a CD20 x CD3 bispecific T-cell engager, which Xencor advanced through Phase 1 clinical development in hematologic cancers. In 2021, Xencor entered a collaboration and license agreement with Janssen Biotech, Inc. to develop and commercial.

Xencor Regains CD20 x CD3 Bispecific T-Cell Engager

PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today reported financial results for the first quarter ended March 31, 2024 and provided a review of recent clinical and business highlights. “We have focused our XmAb® clinical pipeline and discovery activities on bispecific CD3 and CD28 T cell engagers, which continue to show clinical validation for t.

Xencor Reports First Quarter 2024 Financial Results

Xencor (XNCR) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Xencor (XNCR) Moves 14.3% Higher: Will This Strength Last?

PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today announced the appointment of Bart Cornelissen to senior vice president and chief financial officer. Mr. Cornelissen has more than 20 years of experience in corporate financial planning, analysis and transaction support. Before joining Xencor, he was most recently vice president, corporate finance.

Xencor Appoints Bart Cornelissen as Chief Financial Officer

PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today announced that company management will participate at multiple upcoming investor conferences: TD Cowen 44th Annual Health Care Conference Date: Wednesday, March 6, 2024 Presentation Time: 12:50 p.m. ET / 9:50 a.m. PT Location: Boston Leerink Partners Global Biopharma Conference Date: Tuesday, Marc.

Xencor to Present at Upcoming Investor Conferences

Xencor, Inc. (XNCR) Q4 2023 Earnings Call Transcript

News for Xencor Stock (XNCR)